Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8859116 | 0.80 | GABRR1 (0.43) | KDM4EMAPTALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL9033183 | 0.77 | KMT2A (0.34) | MAPTALOX15CA12CA1CA2 | |
| SCHEMBL726708 | 0.72 | MAPT (0.35) | KDM4EMAPTALDH1A1 | |
| SCHEMBL4329451 | 0.72 | MAPT (0.35) | KDM4EMAPTALDH1A1 | |
| SCHEMBL16013532 | 0.72 | — | — | |
| SCHEMBL8756230 | 0.71 | ALDH1A1 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL339998 | 0.71 | MAPT (0.45) | KDM4EMAPTALOX15SMN1; SMN2ALDH1A1 | |
| Trolamine SCHEMBL14990729 | 0.70 | KDM4E (0.44) | KDM4EMAPTALOX15SMN1; SMN2ALDH1A1 | |
| Trolamine SCHEMBL1054050 | 0.70 | SLC7A5 (0.41) | KDM4EMAPTALOX15SMN1; SMN2GABRR1 | |
| Trolamine SCHEMBL1054048 | 0.70 | SLC7A5 (0.41) | KDM4EMAPTALOX15SMN1; SMN2GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | KDM4E 2858/4885MAPT 2799/4885ALOX15 3813/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | KDM4E 2827/4885MAPT 2834/4885ALOX15 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.